Bill 'Best Way To Ensure' Transparency Of Possible Conflicts Of Interest, Editorial States

Main Category: Pharma Industry / Biotech Industry
Also Included In: Medical Students / Training
Article Date: 11 Jun 2008 - 12:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


A report published last week that found three researchers from Harvard Medical School were "vastly underreporting their income from drug companies" offers "striking proof that today's requirements for reporting payments from industry -- essentially an honor system in which researchers are supposed to reveal their outside income to their institutions" -- must "be strengthened," a New York Times editorial states. According to the editorial, the results of the report -- published in the Congressional Record by Sen. Chuck Grassley (R-Iowa) -- are "particularly troublesome" because studies conducted by the three researchers have "helped fuel an explosion in the use of powerful antipsychotic drugs to treat children."

The editorial states, "Although supporters praise the most prominent of the trio" -- Joseph Biederman -- "as a visionary who has saved many lives, critics complain that the Harvard studies have been too small and loosely designed to provide conclusive results," adding, "Critics say they also were subject to biased interpretation through use of a subjective rating scale." The editorial states, "At this point, it is not clear whether the researchers inadvertently failed to comply with reporting rules or consciously sought to hide their sizable incomes from drug companies." However, "it is clear that relying on researchers to report their outside incomes and on universities and hospitals to police the disclosures won't suffice," according to the editorial.

A bill introduced by Grassley and Sen. Herb Kohl (D-Wis.) that would "require drug and device makers to report annually any payments to doctors that exceed $500 a year ... is the best way to ensure that conflicts of interest are transparent to all," the editorial concludes (New York Times, 6/10).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Article adapted by Medical News Today from original press release.
Visit our pharma industry / biotech industry section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "Bill 'Best Way To Ensure' Transparency Of Possible Conflicts Of Interest, Editorial States." Medical News Today. MediLexicon, Intl., 11 Jun. 2008. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/110773.php>

APA
Kaiser. (2008, June 11). "Bill 'Best Way To Ensure' Transparency Of Possible Conflicts Of Interest, Editorial States." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/110773.php.

Please note: If no author information is provided, the source is cited instead.


Pharma Industry / Biotech Industry

Most Popular Articles



Follow Our Pharma Industry News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pharma Industry / Biotech Industry Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »